Patient stories

      Test
      Focus Area
      Format
      Evidence
FILTER BY TESTS
DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma TissueCypher DecisionDx-UM IDgenetix

Melanoma diagnosis, now what?

Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon

From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis

Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon
Click to play "Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story" video

Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story

As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon
Click to play "DecisionDx-Melanoma Helps to Guide Patient Management Decisions" video

DecisionDx®-Melanoma Helps to Guide Patient Management Decisions

Dr. Aaron Farberg speaks about how the DecisionDx-Melanoma test results helps better identify a patient's risk of metastasis and how some patients may be able to forgo a SLNB procedure.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "DecisionDx-Melanoma Increases the Risk Prediction that is Currently Available for Patients" video

DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients

Dr. Clay Cockerell speaks on how the DecisionDx-Melanoma test is not intended to replace staging systems but how using GEP can increase risk prediction for patients with Stage I-III melanoma.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "Molecular Prognostic Tests are Changing Management of Dermatologic Cancer" video

Molecular Prognostic Tests are Changing Management of Dermatologic Cancers

Learn more about how Gene Expression Profiling (GEP) can be used to individualize patient care and management of melanoma.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "More Accurately Predicting Individual Risk of Recurrence or Metastasis" video

More Accurately Predicting Individual Risk of Recurrence or Metastasis

DecisionDx- Melanoma can be used to determine what level of follow-up, imaging, and referrals are appropriate for individual patients.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "SLNB Surgical Procedures: Improving Patient Selection" video

SLNB Surgical Procedures: Improving Patient Selection

DecisionDx-Melanoma can guide the decision of whether to perform or forgo a sentinel lymph node biopsy.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "The Limitations of Traditional Approaches" video

The Limitations of Traditional Approaches

Using staging systems alone may miss patients with aggressive tumor biology. Listen in, to learn how DecisionDx-Melanoma addresses these limitations by improving prognostic accuracy.

DecisionDx-Melanoma
Watch Story Link icon